vTv has discovered a small molecule RAGE inhibitor being developed by Cantex under a global development and commercialization contract
HIGH POINT, NC, May 24, 2023 (Globe Newswire) — vTv Therapeutics Inc. (Nasdaq: VTVT) is focused on developing insulin adjuvant therapies for the treatment of type 1 diabetes (“T1D”). A clinical stage biopharmaceutical company. ”), today announced that the United States Patent and Trademark Office recently issued a patent to Cantex Pharmaceuticals, Inc. covering claims relating to the use of azerilagon as a potential treatment for glioblastoma multiforme (GBM). Azerilagon is a small molecule inhibitor of the receptor for advanced glycation end products (RAGE) discovered by vTv and licensed to Cantex Pharmaceuticals.Cantex is indicated for the neoadjuvant treatment of metastatic pancreatic cancer, breast cancer, and ongoing clinical trials of azelilagon in patients with COVID-19 to prevent acute kidney injury, with clinical trials of azerilagon expected to begin soon in newly diagnosed glioblastoma and brain metastases Stereotactic Radiosurgery Earlier this year, Kantex received Orphan Drug Designation from the Food and Drug Administration for azerilagon for the treatment of glioblastoma.
On June 22, 2021, vTv and Cantex entered into a licensing agreement under which Cantex obtained exclusive worldwide rights to develop and commercialize Azerilagon. Under the terms of the agreement, in the event of successful development and launch, the two companies will share downstream profits based on a tiered arrangement.
Prior to the Cantex agreement, vTv was developing Azerilagon for the treatment of Alzheimer’s disease. Through these efforts, vTv has generated a large body of clinical data supporting the safety and tolerability profile of azerilagon. Evidence suggests that RAGE-ligand interactions play an important role in various inflammatory diseases, not just cancer.
“I would like to congratulate Cantex on receiving this significant addition to its Azerilagon patent assets covering the use of GBM as a potential therapeutic. Together with the drug designation, Kantex is building strong protections around this novel small molecule RAGE inhibitor with the aim of maximizing commercial opportunities for Azerilagon if successful in clinical development said Paul Secri, President and Chief Executive Officer. Executive Officer of vTv Therapeutics. “We will continue to monitor our ongoing GBM research and development efforts for Cantex in other indications involving RAGE.”
About Azerilagon
Azerilagon is a small molecule administered orally once daily that inhibits the interaction of the advanced glycation end product receptor (known as RAGE) with specific ligands such as HMGB1 and S100 proteins within the glioblastoma microenvironment. increase. By interfering with the interaction of RAGE with these ligands, azerilagon may inhibit glioblastoma and overcome its resistance to effective therapy. Azerilagon was originally being developed for Alzheimer’s disease by vTv Therapeutics and licensed from Cantex. Clinical safety data from these trials, in which more than 2000 people were treated for up to 18 months, demonstrate that azerilagon is very well tolerated. Cantex is also developing Azerilagon for the treatment of brain metastases, pancreatic cancer and breast cancer. Additionally, a Phase 2/3 trial is currently enrolling hospitalized COVID-19 patients and is evaluating the efficacy of azerilagon in preventing acute kidney injury.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates focused on treatment programs for type 1 diabetes and cystic fibrosis-related diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy and pancreatic cancer. For more information, please visit www.vtvtherapeutics.com.
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing innovative treatments for cancer and other life-threatening conditions where new treatments are urgently needed. For more information, please visit www.cantex.com.
Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, including statements regarding possible FDA approval. These forward-looking statements include, but are not limited to, “anticipates,” “believes,” “may,” “estimates,” “expects,” “intends,” “may,” and “plans.” identified by the use of forward-looking terminology, including the term “”, “potential”, “predict”, “anticipate”, “should”, “target”, “would”, “would” and in each case those negative or other various or similar terms. All statements other than statements of historical fact contained in this release, including statements about contracts and transactions in this release, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors, including the risk that FDA approval may not be received in a timely manner or may not be approved at all, which may affect our actual Our results, performance and achievements may differ materially from future results. , performance or achievements expressed or implied by forward-looking statements; Important factors that could cause our results to differ from expectations include those discussed in our Annual Report on Form 10-K and other filings with the SEC under the heading “Risk Factors.” included. These forward-looking statements reflect our views regarding future events as of the date of this release, are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent only our estimates and assumptions as of the date of this release and, except as required by law, we do not make any assumptions as a result of new information or forward-looking statements. We undertake no obligation to update or publicly review any forward-looking statements, whether or not Events or other after the date of this release. Subsequent events and developments are expected to change our views. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, disposals, joint ventures or investments that we may make. We qualify all forward-looking statements by these cautionary statements.
contact address:
Investor:
Lee Roth
Burns McClellan
lroth@burnsmc.com
media:
Celina Husain / Dr. Robert Fram
Burns McLellan Company
shusain@burnsmc.com / rflamm@burnsmc.com
